BSTC BioSpecifics Technologies Corp

62.01
0  0%
Previous Close 62.01
Open
Price To Book 4.42
Market Cap 451,860,793
Shares 7,286,902
Volume 0
Short Ratio
Av. Daily Volume 71,701

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
BLA filing 2H 2019.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 data released October 31, 2018 - primary endpoint of safety and tolerability met.
XIAFLEX
Uterine fibroids